Search

Your search keyword '"Wenlei Jiang"' showing total 143 results

Search Constraints

Start Over You searched for: Author "Wenlei Jiang" Remove constraint Author: "Wenlei Jiang" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
143 results on '"Wenlei Jiang"'

Search Results

1. Stem cell-derived cardiomyocytes expressing a dominant negative pacemaker HCN4 channel do not reduce the risk of graft-related arrhythmias

2. Global harmonization of immediate‐release solid oral drug product bioequivalence recommendations and the impact on generic drug development

3. Research and application of key technologies of intelligent mining area cloud platform based on 4DGIS

4. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.

5. Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: Physicochemical Characterization

6. Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: Biodistribution after Intravenous Dosing in Rats

7. Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: In Vitro Cellular Uptake

10. Generic lamotrigine extended‐release tablets are bioequivalent to innovator drug in fully replicated crossover bioequivalence study

11. iBCS: 2. Mechanistic Modeling of Pulmonary Availability of Inhaled Drugs versus Critical Product Attributes

12. iBCS: 1. Principles and Framework of an Inhalation-Based Biopharmaceutics Classification System

13. In Vitro Matured Human Pluripotent Stem Cell–Derived Cardiomyocytes Form Grafts With Enhanced Structure and Function in Injured Hearts

15. Considerations for the Forced Expiratory Volume in 1 Second‐Based Comparative Clinical Endpoint Bioequivalence Studies for Orally Inhaled Drug Products

16. SNRPB promotes cell cycle progression in thyroid carcinoma via inhibiting p53

17. Research and Education Needs for Complex Generics

18. Challenges and opportunities in the development of complex generic long-acting injectable drug products

19. Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate

20. Preferences for and Experiences With Pill Appearance Changes: National Surveys of Patients and Pharmacists

22. Development of In Vitro Dissolution Testing Methods to Simulate Fed Conditions for Immediate Release Solid Oral Dosage Forms

23. Analysis of phospholipids and triacylglycerols in intravenous lipid emulsions

24. Lack of association between generic brittleness and neuropsychiatric measures in patients with epilepsy

25. Effects of Dissolution Medium pH and Simulated Gastrointestinal Contraction on Drug Release From Nifedipine Extended-Release Tablets*

26. Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography–Inductively Coupled Plasma–Mass Spectrometric Approach

27. A Survey of Patients’ Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications

28. Exploring generic brittleness and the demographic factors for its susceptibility in patients with epilepsy

29. Analysis of verteporfin liposomal formulations for phospholipids and phospholipid degradation products by liquid chromatography-mass spectrometry (LC-MS)

30. The Global Bioequivalence Harmonisation Initiative (GBHI): Report of EUFEPS/AAPS fourth conference

31. Abstract 307: Lymph node accumulation of theranostic lipid-based nanoparticles in healthy and diseased models: Preliminary results comparing nanoparticle morphology and targeting

32. IntegratingIn Vitro, Modeling, andIn VivoApproaches to Investigate Warfarin Bioequivalence

33. In Vitro Evaluation of Nasogastric Tube Delivery Performance of Esomeprazole Magnesium Delayed-Release Capsules

34. Dissolution Failure of Solid Oral Drug Products in Field Alert Reports

35. Equivalence of complex drug products: advances in and challenges for current regulatory frameworks

36. Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence

37. Tailored theranostic apolipoprotein E3 porphyrin-lipid nanoparticles target glioblastoma

38. Lack of Association of Generic Brittle Status with Genetics and Physiologic Measures in Patients with Epilepsy

39. Quantification of phospholipid degradation products in liposomal pharmaceutical formulations by ultra performance liquid chromatography-mass spectrometry (UPLC-MS)

40. The global bioequivalence harmonisation initiative: Report of EUFEPS/AAPS third conference

41. Quantitative analysis of cholesterol oxidation products and desmosterol in parenteral liposomal pharmaceutical formulations

42. Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: 'Drug Products, Including Biological Products, that Contain Nanomaterials'

43. An in vitro approach for evaluating the oral abuse deterrence of solid oral extended-release opioids with properties intended to deter abuse via chewing

44. Therapeutic Drug Monitoring, Electronic Health Records, and Pharmacokinetic Modeling to Evaluate Sirolimus Drug Exposure–Response Relationships in Renal Transplant Patients

45. Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence

46. Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir

47. Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy

48. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values

49. Evaluation of Switching Patterns in FDA's Sentinel System: A New Tool to Assess Generic Drugs

50. Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome

Catalog

Books, media, physical & digital resources